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N -Acetylaspartate (NAA) is employed as a non-invasive marker for neuronal health using
proton magnetic resonance spectroscopy (MRS).This utility is afforded by the fact that NAA
is one of the most concentrated brain metabolites and that it produces the largest peak in
MRS scans of the healthy human brain. NAA levels in the brain are reduced proportionately
to the degree of tissue damage after traumatic brain injury (TBI) and the reductions parallel
the reductions in ATP levels. Because NAA is the most concentrated acetylated metabolite
in the brain, we have hypothesized that NAA acts in part as an extensive reservoir of
acetate for acetyl coenzyme A synthesis. Therefore, the loss of NAA after TBI impairs
acetyl coenzyme A dependent functions including energy derivation, lipid synthesis, and
protein acetylation reactions in distinct ways in different cell populations. The enzymes
involved in synthesizing andmetabolizing NAA are predominantly expressed in neurons and
oligodendrocytes, respectively, and therefore some proportion of NAA must be transferred
between cell types before the acetate can be liberated, converted to acetyl coenzyme A
and utilized. Studies have indicated that glucose metabolism in neurons is reduced, but
that acetate metabolism in astrocytes is increased following TBI, possibly reﬂecting an
increased role for non-glucose energy sources in response to injury. NAA can provide
additional acetate for intercellular metabolite trafﬁcking to maintain acetyl CoA levels after
injury. Here we explore changes in NAA, acetate, and acetyl coenzyme A metabolism in
response to brain injury.
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INTRODUCTION
N-acetylaspartate (NAA) is one of the most abundant brain
metabolites and is highly concentrated in neurons, but it remains
to be determined why neurons synthesize so much of this particu-
lar acetylated amino acid. Early research implicated NAA in lipid
synthesis in the brain, especially during postnatal myelination.
Other early investigations connected NAA to carbon transport
and energy metabolism in neuronal mitochondria. Subsequently
it was discovered that mutations in the gene for the enzyme that
deacetylates NAA, known as aspartoacylase or ASPA, lead to the
fatal neurodegenerative disorder known as Canavan disease. After
more than two decades of research the precise connection between
the inability to deacetylate NAA and the pathogenesis of Canavan
disease remains a matter of ongoing investigation. One line of
research has focused on the lack of catabolism leading to a toxic
buildup of NAA in the brain as the primary etiological component.
Another line of research has suggested that the lack of catabolism
results in an acetate deﬁciency in oligodendrocytes during brain
development that subsequently limits acetyl coenzyme A (acetyl
CoA) availability during this critical period of myelination. There
is experimental support for both mechanisms, and it is possible
that both are operative.
Continuing work onNAA over the last two decades has focused
almost exclusively on the utility of NAA measurements in various
neuropathological conditions using proton magnetic resonance
spectroscopy (MRS). NAA provides the largest single peak on pro-
tonMRS spectra of the healthy human brain, and brainNAA levels
are found to be reduced in a majority of neuropathologies includ-
ing traumatic brain injury (TBI). The loss of NAA after TBI is
paralleled by a loss of ATP, acetyl CoA, and other metabolites asso-
ciated with energy metabolism (Vagnozzi et al., 2007) indicating a
substantial impact on neuroenergetics. The connections between
NAA and brain energy metabolism are not entirely clear, but it
seems likely that they involve acetyl CoA generation andutilization
(Ariyannur et al., 2010a). Acetyl CoA is at the crossroads of energy
derivation, storage, and utilization, and is also involved in cel-
lular control of protein function and gene transcription through
acetylation reactions. NAA is synthesized from acetyl CoA and
aspartate, and because of the exceptionally high concentration
in the human brain (∼10 mM) some proportion of acetyl CoA
must be utilized to maintain NAA levels, and that proportion may
change with brain injury. Signoretti and colleagues have shown
that severe brain injury results in a very rapid drop in NAA levels
that is paralleled by a similar reduction in ATP levels, suggesting
that NAA is utilized rapidly in response to injury. Indeed, NAA
levels are reduced by over 20% within 1 min of severe TBI in rats
at a time when ATP levels are only reduced by ∼10% (Signoretti
et al., 2001). These investigators also found that over time after
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injury, recovery of NAA levels “has been observed only in concert
with restoration of ATP” (p. 988) further linking NAA with post-
injury neuroenergetics. As such, the study of NAA metabolism
may provide unique insights into how the brain’s energy sys-
tems respond to injury and recover throughout the healing
process.
NAA SYNTHESIS AND LOCALIZATION
Early investigations into the amino acid content of protein-free
brain extracts found a large proportion of “bound aspartic acid,”
which represented the largest quantity of any conjugated amino
acid present in the brain (Tallan et al., 1954). Because the aspar-
tic acid conjugate was ninhydrin-negative it was concluded that
it was N-substituted. Subsequent work demonstrated that the
compound was NAA (Tallan et al., 1956). Early studies on the
incorporation of 14C-labeled glucose into NAA in the adult cat
brain suggested low turnover rates, and these ﬁndings were inter-
preted to mean that NAA was metabolically inert (Margolis et al.,
1960). Nonetheless the high concentration of NAA in the brain
led a small number of researchers to begin investigating how NAA
was synthesized in the nervous system.
ASPARTATE N -ACETYLTRANSFERASE
The earliest studies on NAA synthesis indicated that an enzyme
was present in the soluble fraction of brain homogenates with
an absolute speciﬁcity for acetyl CoA and aspartate (Goldstein,
1959). This same study reported that a mechanism existed for
the hydrolysis of NAA in the brain, as most of the NAA in rat
brain supernatants was lost on 2–3 h incubations at 37◦C. These
initial ﬁndings on NAA synthesis in brain homogenates were
called into question by Jacobson (1959), who only detected NAA
synthesis in minced brain preparations, but not in cell-free prepa-
rations. Jacobson also found that the incorporationof radiolabeled
acetate into NAA was highest during brain development while
myelination was taking place. This issue was revisited by Knizley
(1967) who observed NAA synthesis from radiolabeled aspartate
in a particulate fraction from cat brain extracts, but not in the
water soluble fractions. Knizley designated the enzyme activity
he observed as acetyl-CoA-L-aspartate N-acetyltransferase (ASP-
NAT). Goldstein (1969) returned to the study of NAA synthesis a
decade after his ﬁrst report, and in these later studies he concluded
that NAA synthesis was associated with the particulate fraction
from brain, including microsomal and mitochondrial fractions.
He also reported that the synthetic capacity for NAA was substan-
tially higher than reported previously indicating that NAAwas not
metabolically inert. Research into NAA synthesis did not resume
until a number of years later when Truckenmiller et al. (1985) sol-
ubilized and characterized the enzyme from brain homogenates
and showed that the enzyme acetylated aspartate 10 times more
efﬁciently than it acetylated glutamate. They also found that the
enzyme showed a 10-fold variation in activity levels in the nervous
system, with the highest activity in brainstem and spinal cord,
and the lowest activity in the retina. No enzyme activity could be
detected in the pituitary gland, or in heart, liver, and kidney. The
enzyme was designated as L-aspartate N-acetyltransferase (Asp-
NAT or ANAT) and given the enzyme commission (EC) number
of EC 2.3.1.17.
After another protracted gap in the research, two laborato-
ries took up the task of purifying Asp-NAT and attempted to
determine its subcellular localization. Madhavarao et al. (2003)
employed several techniques to purify Asp-NAT activity from
brain homogenates, including anion exchange chromatography,
native gel electroelution, and size exclusion HPLC. They reported
a number of ﬁndings on Asp-NAT activity including conﬁrming
that the enzyme was highly speciﬁc for aspartate, with less than
3% activity directed to the acetylation of glutamate, asparagines,
or glutamine, and no detectable capacity to acetylate the dipep-
tide aspartylglutamate. Looking at enzyme activity relative to the
concentration of the two substrates, aspartate and acetyl CoA,
they found the Km values to be 580 and 58 μM, respectively.
They also noted end-product inhibition of the enzyme by NAA
and coenzyme A (IC values of 850 and 420 μM, respectively).
Size exclusion chromatography and native gel electrophoresis both
indicated that the enzyme was most likely associated with a pro-
tein complex that had a molecular weight of ∼670 kDa. Finally,
subfractionation studies using differential centrifugation showed
that enzyme activity was present in myelin, mitochondrial, and
synaptosomal fractions. Very similar results were reported by
Lu et al. (2004) who used differential centrifugation methods to
fractionate brain homogenates into mitochondrial, intermedi-
ate, and microsomal fractions and found Asp-NAT activity in
all three. Lu et al. found that the microsomal fractions con-
tained the greatest percentage of Asp-NAT activity, although a
signiﬁcant proportion of total activity was lost upon density
gradient centrifugation. In addition Lu et al. reported some-
what higher enzyme Km values for aspartate and acetyl CoA
(910 and 169 μM, respectively). With regard to the subcel-
lular localization data based on subfractionation methods one
caveat should be noted. If neuronal mitochondria are indeed
a site of signiﬁcant Asp-NAT localization then any methods
employing brain homogenates will underestimate the mitochon-
drial component because neuronal mitochondria only comprise
a subset of all brain mitochondria and it is difﬁcult to iso-
late the neuronal mitochondria from synaptic terminals and
myelin.
Using radiolabeled precursors to quantify mitochondrial and
cytosolic synthetic sites our laboratory employed two metabolic
precursors for NAA synthesis that would be utilized differen-
tially in the two sites. We hypothesized that aspartate, which is
exported from mitochondria in exchange for glutamate, would
be preferentially acetylated in the cytoplasm, whereas malate,
which is taken up avidly by mitochondria, would be converted
to aspartate (via transamination of oxaloacetate) and acety-
lated predominantly in the mitochondrial compartment (Arun
et al., 2009). In this study employing a cell culture system to
model NAA synthesis, as expected, both substrates resulted in
the synthesis of radiolabeled NAA. However, the ratio of radi-
olabeled NAA to radiolabeled aspartate was found to be over
20 times greater when malate was used as substrate, as com-
pared with using labeled aspartate as substrate. This ﬁnding
was interpreted to indicate that the mitochondrial compartment
provided a greater contribution to NAA synthesis than the cyto-
plasmic compartment. Using the same cell culture system, another
research group recently found that the electron transport chain
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inhibitor antimycin A reduced NAA levels, further substantiating
that some proportion of NAA synthesis occurs in mitochondria
(Li et al., 2013).
In 2010 the gene for Asp-NAT was ﬁnally identiﬁed as Nat8l
which opened upnew avenues for characterizing and localizing the
enzyme (Ariyannur et al., 2010a; Wiame et al., 2010). Wiame et al.
(2010) used transfection of Myc-tagged Nat8l in Chinese hamster
ovary (CHO) cells and primary neuronal cultures to show that
Asp-NAT protein colocalized with endoplasmic reticulum, but
not with Golgi apparatus or mitochondria. These investigators
also used targeting prediction programs to analyze the Nat8l gene
sequence and did not ﬁnd a mitochondrial targeting sequence.
Using immunohistochemistry in a neuronal cell line in culture,
Ariyannur et al. (2010a) employed afﬁnity puriﬁed antibodies to
a speciﬁc Nat8l peptide sequence and found partial colocalization
with mitochondria. In a more recent study using transfection of
the gene for Asp-NAT into several cell types, Tahay et al. (2012)
reported that Asp-NAT expression was restricted to the endoplas-
mic reticulum, and was not present in mitochondria. Further,
they used transfection of truncated forms of the gene to show
that Asp-NAT appeared to be targeted to the ER membrane by
a hydrophobic loop that connects two regions of the catalytic
domain.
NAA SYNTHESIS AND THE MITOCHONDRIAL MALATE-ASPARTATE
SHUTTLE
Mitochondria express a number of solute carrier complexes that
move anaplerotic metabolites into the mitochondrial matrix and
cataplerotic metabolites out of the matrix. The primary mito-
chondrial aspartate-glutamate carrier expressed in brain, heart,
skeletal muscle, and several other tissues is known as aralar1 (Del
Arco et al., 2002), which is part of a larger complex that comprises
the so-called mitochondrial malate-aspartate shuttle. The malate-
aspartate shuttle functions to move reducing equivalents into the
mitochondrial matrix in the form of malate, whereas the major
mitochondrial output through this complex is aspartate. Specif-
ically, aralar1 moves cytoplasmic glutamate into mitochondria,
while moving mitochondrially synthesized aspartate out. With-
out aralar1, brain mitochondrial glutamate import and aspartate
export are crippled. Studies with aralar1 knockout mice showed
a dramatic drop in brain aspartate levels, with a concomitant
reduction in NAA synthesis (Jalil et al., 2005; Satrustegui et al.,
2007).
The connection between a lack of aralar1 expression and
dramatically reduced NAA synthesis has at least two potential
explanations. First, as suggested by Jalil et al. (2005) it could
be due to the lack of mitochondrial aspartate output, which
in turn would limit substrate availability for microsomal Asp-
NAT to synthesize NAA. The other possible explanation is that
the lack of glutamate uptake into neuronal mitochondria pre-
vents intramitochondrial aspartate synthesis via the aspartate
aminotransferase reaction which converts glutamate and oxaloac-
etate into α-ketoglutarate and aspartate. In this case the lack
of intramitochondrial aspartate synthesis would be the limiting
factor in NAA synthesis, leading to decreases in NAA levels. It
is also possible that both of these mechanisms are responsible
for the large drop in NAA levels observed in aralar1-deﬁcient
mice. One of the more interesting outcomes of aralar1 deﬁ-
ciency in addition to the large decrease in brain NAA levels
is hypomyelination (Jalil et al., 2005; Wibom et al., 2009). The
hypomyelination is hypothesized to result from the lack of
availability of NAA and this conclusion is supported by the
fact that galactocerebrosides, one of the myelin lipid classes
that are reduced in Canavan disease (Madhavarao et al., 2005;
Arun et al., 2010b), were also reduced in aralar1 knockout
mice.
NAA SYNTHESIS RATES
Burri et al. (1991) were the ﬁrst to investigate NAA synthesis at
speciﬁc time points during brain development and showed that
Asp-NAT activity in rats increased almost linearly from postnatal
day 3 to day 35, and the increase in enzyme activity was par-
alleled by a corresponding increase in brain NAA levels. Using
13C-labeled glucose infusions and 13C-MRS of tissue extracts from
several brain regions Tyson and Sutherland (1998) found the
incorporation rate into labeled NAA was relatively low as com-
pared with the labeling of glutamate, or the neuronal dipeptide
N-acetylaspartylglutamate (NAAG). In this study the fractional
enrichment of NAA after a 200 min 13C-glucose infusion was
3%, whereas the fractional enrichment of NAAG was 20% and
that of glutamate 25.2%, indicating that in the uninjured adult
rat brain the turnover of NAA was relatively slow. In the ﬁrst
use of 13C-MRS to study NAA synthesis non-invasively in the
human brain, Moreno et al. (2001) estimated that NAA was syn-
thesized in humans at a rate of 9.2 ± 3.9 nmol/min/g. These
results were based on measurements from four adults and two
children using 13C-labeled glucose infusions to investigate 13C
enrichment in NAA. The calculated NAA synthesis rates from
glucose in the four adults were very similar averaging around
8.9 ± 1 nmol/min/g, whereas the calculated rates in the two con-
trol children were quite divergent (4.3 and 15.1 nmol/min/g).
Compared with the synthesis rates of other brain metabolites
the NAA synthesis rate was one to two orders of magni-
tude lower (e.g., glutamine synthesis rate = 400 nmol/min/g).
Moreno et al. also measured NAA synthesis rates in the brains
of three children with Canavan disease. NAA concentrations in
the brains of Canavan disease patients are elevated, and the
synthesis rates are reduced by about 60% relative to controls
(3.6 ± 0.1 nmol/min/g).
Overall these results indicate that NAA synthesis in the resting
brain is relatively slow when compared with other rapidly synthe-
sized brain metabolites and the total metabolite ﬂux through the
TCA cycle. However, the incorporation of carbon from glucose
into the aspartate moiety of NAA is an indirect process involving
numerous enzymatic steps and dilutionwith TCA cycle intermedi-
ates such as oxaloacetate. It was observed that 13C does not appear
in NAA until 50 min after 13C-glucose infusion was initiated. This
is a substantially longer delay than in the case of glutamate or
aspartate, in which 13C enrichment could be observed as early as
10 min after the start of labeled glucose infusion. Data on the
relatively slow but continuous synthesis of NAA in resting adult
animals ismore suggestive of ametabolic role in biosynthetic reac-
tions (e.g., lipid synthesis and protein acetylation reactions) than
in a direct energy derivation role.
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Additional studies of NAA synthesis using 13C mass-
labeled glucose indicated similar synthetic rates for NAA of
∼10–12 nmol/min/g (0.6–0.7μmoles/g/h) with a calculated com-
plete turnover occurring every 2–3 days (Choi and Gruetter,
2004). A later study using similar methods found a lower rate
of synthesis in adult rats of only 0.19 μmoles/g/h (Xu et al.,
2008) and these authors suggested that the discrepancy between
their results and those of Choi and Gruetter may have been
due to the localization and size of the voxel used for measure-
ments. The Choi and Gruetter study used a larger voxel that
included substantial amounts of white matter, whereas the stud-
ies by Xu et al. employed a smaller voxel localized to cerebral
gray matter. This would suggest that NAA turnover was signiﬁ-
cantly higher in white matter. However, it is important to note
that all of these studies were done in adult rats, rather than
in developing rats when myelination is taking place. It is likely
that if these experiments were repeated in developing rats that
the observed NAA synthesis rates would be higher, especially
in white matter. Another important consideration is that NAA
synthesis rates have never been assessed after brain injury. One
preliminary investigation examined NAA synthesis rates using
13C-MRS with isotope-labeled glucose infusions in Alzheimer
patients to determine if the rate of NAA synthesis was regulated
in disease states. They found that NAA synthesis was substan-
tially higher in Alzheimer patients, and they hypothesized that
this was reﬂective of a compensatory mechanism where a loss
of neurons resulted in higher synthesis rates in the remaining
neuronal population (Harris et al., 2006). It will be important
for future studies to examine the rate of NAA synthesis from
precursors in experimental TBI to determine if, as is the case
with Alzheimer disease, the rate is increased signiﬁcantly during
recovery.
LOCALIZATION OF NAA
The neuronal localization of NAA was inferred in early studies.
Benuck and D’Adamo (1968) tested NAA synthesis and hydrolysis
in several tissues and found that only the nervous system synthe-
sizedNAA,but thatmany tissues including kidney, liver, heart, and
mammary gland catabolized NAA (D’Adamo and Yatsu, 1966).
Interestingly, they found that some tissues, for example kidney,
avidly took up andmetabolizedNAA toCO2,whereas other tissues
took upNAA and converted it to lipids, including brain andmam-
mary gland. They concluded that NAAwas only synthesized in the
nervous system, but that it could be metabolized in many tissues.
Nadler and Cooper (1972a) analyzed various CNS tumors and
compared NAA levels to normal brain tissue levels and upon ﬁnd-
ing that tumors had substantially lower levels of NAA concluded
that NAA was predominantly localized in neurons. Chromato-
graphic analyses of different tissue extracts indicated that NAA
was present in the brain at concentrations over 100 times greater
than that found in non-neural tissues, and this ﬁnding further
strengthened the case that neurons were the major source of NAA
(Miyake et al., 1981). An in vitro investigation of various brain cell
types using MRS and high performance liquid chromatography
indicated that neurons such as cerebellar granule cells contained
high levels of NAA, whereas astrocytes and mature oligodendro-
cytes contained undetectable levels (Urenjak et al., 1992). High
NAA levels were also found in oligodendrocyte-type-2 astrocyte
(O-2A) progenitor cells and immature oligodendrocytes.
Utilizing speciﬁc monoclonal (Simmons et al., 1991) and poly-
clonal (Moffett et al., 1991) antibodies and specialized tissue ﬁxa-
tionmethods, the neuronal localization of NAAwas conﬁrmed via
immunohistochemistry. Improvements in those methods allowed
for the detailed visualization of NAA in brain tissue sections,
and showed that the distribution of NAA in the nervous system
did not match the distribution pattern for the related neuronal
dipeptide NAAG (Moffett et al., 1993; Moffett and Namboodiri,
1995, 2006). NAA was observed in most neurons, with staining
intensities ranging from moderate in hippocampal granule cells
to strong in cortical pyramidal neurons. NAA was also observed
in the axons of numerous ﬁber tracts such as the corpus callosum
(Figure 1).
NAA, ASPA AND LIPID SYNTHESIS
The ﬁrst description of the speciﬁc enzymatic activity of ASPAwas
given by Birnbaum et al. (1952). They distinguished aminoacy-
lase I and aminoacylase II derived from kidney based on substrate
speciﬁcity. Aminoacylase I had a broad speciﬁcity forN-acetylated
amino acids, whereas aminoacylase II (ASPA) was highly speciﬁc
to NAA. As noted above, Benuck andD’Adamo (1968) found both
uptake and utilization of NAA in various non-neural tissues. They
showed that radiolabeled NAAwasmetabolized to both fatty acids
and to CO2 demonstrating that NAA-derived acetate could be
used for either energy production or lipid synthesis, twometabolic
pathways tied directly to acetyl CoA utilization. This implied that
after NAA is hydrolyzed byASPA, the resultant acetate is converted
to acetyl CoA for further use. Nadler and Cooper (1972b) found
that radiolabeled NAA when injected into the brain was metab-
olized rapidly by deacylation in a relatively small but very active
metabolic compartment, and linked the metabolism of NAA to
the TCA cycle and glutamate synthesis. D’Adamo et al. (1968)
injected NAA that had been radiolabeled on the acetate into the
brains of developing rats and found that the label was incorporated
mainly into long chain C16 and C18 fatty acids. They proposed
that NAA was a mechanism of carbon transport out of mitochon-
dria for fatty acid synthesis. However, at the time it was not known
that NAA was present primarily in neurons (Urenjak et al., 1992;
Moffett and Namboodiri, 1995), whereas ASPA was present pri-
marily in oligodendrocytes (Baslow et al., 1999; Klugmann et al.,
2003; Madhavarao et al., 2004; Moffett et al., 2011), indicating that
trans-cellular transport of NAA was involved in some or most of
its metabolism in the CNS.
NAA AND LIPID SYNTHESIS
Neurons provide key metabolites to their ensheathing oligoden-
drocytes for the purposes of myelination, myelin maintenance,
and myelin sheath repair, including choline, palmitate, acetate,
phosphate, and ethanolamine (Ledeen, 1984). NAA is among
the trophic neuronally derived metabolites that are transferred
to oligodendrocytes for use in myelination and myelin repair. In
order forNAA-derived acetate to participate in lipid synthesis after
ASPA-mediated hydrolysis the acetate groups must be activated
by conversion to acetyl CoA (D’Adamo and Yatsu, 1966; Burri
et al., 1991; Mehta and Namboodiri, 1995). NAA is not a primary
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FIGURE 1 | Immunohistochemistry of NAA in specially fixed
rat brain tissue using highly purified polyclonal antibodies to
protein-coupled NAA. NAA immunoreactivity was observed in
virtually all ﬁber pathways, such as the corpus callosum [cc in (A)].
In gray matter, NAA immunoreactivity was strong in large cortical
pyramidal neurons [arrows in (B)], and moderate in smaller cortical
neurons (B). NAA was also observed in many neuronal dendrites.
Methods described in Moffett and Namboodiri (1995). Images taken
with 20× (A) and 40× (B) objectives. LV, lateral ventricle; v, blood
vessel.
source of acetyl CoA as is the case with pyruvate. The synthesis of
NAA requires the utilization of existing acetyl CoA and therefore
NAA synthesis consumes a portion of brain acetyl CoA stores.
Therefore NAA may be acting as a storage and transport form
of acetate in the CNS that can be used for subsequent de novo
synthesis of acetyl CoA, especially in oligodendrocytes (Ariyannur
et al., 2010a). Ledeen and coworkers injected radiolabeled NAA
into the eye to show that when NAA was transported down the
axons the radioactive acetate was incorporated into the myelin
lipids in the optic nerve (Chakraborty et al., 2001). This showed
thatNAA in neurons supplies some of acetyl groups for the synthe-
sis of myelin-associated lipids in oligodendrocytes. NAA supplies
∼1/3 of the requisite acetyl CoA for myelin lipid synthesis dur-
ing brain development and myelination (Wang et al., 2009), with
the remaining 2/3 being supplied by citrate produced in oligo-
dendrocyte mitochondria (Figure 2). Citrate is produced from
acetyl CoA in mitochondria, and the citrate is exported to the
cytoplasm where it is reconverted to acetyl CoA by the enzyme
citrate lyase (also known as ATP citrate lyase). We have proposed
that NAA may be acting as a parallel pathway for supplying addi-
tional acetyl CoA to oligodendrocytes (Moffett et al., 2007), which
would be more critical during the period of intensive myelina-
tion that begins after birth. Unlike citrate, which is converted to
acetyl CoA in the same cell, NAA would be transferred to oligo-
dendrocytes where it is reconverted to acetyl CoA by the sequential
action of ASPA and acetyl CoA synthase-1 (AceCS1, discussed in
more detail below). It is unknown what percentage of acetyl CoA
associated with myelin repair and remyelination is derived from
NAA after brain injury. Studies using NAA radiolabeled on the
acetatemoiety could be employed to study this using experimental
TBI in rats.
ASP-NAT EXPRESSION IN BROWN ADIPOSE TISSUE
A recent study revealed that Nat8l, the gene encoding the NAA
biosynthetic enzyme Asp-NAT, is expressed strongly in brown
adipose tissue (BAT; Pessentheiner et al., 2013). To date this is
the only tissue other than the CNS where strong Nat8l expres-
sion has been found. Expression in BAT was similar to expression
levels in the brain, whereas expression in white adipose tissue
was much lower. Pessentheiner and colleagues found that over-
expression of Nat8l in BAT cells increased glucose incorporation
into neutral lipids, and increased lipolysis suggesting that Asp-
NAT expression facilitated lipid turnover in these cells. These
investigators also found that when Nat8l expression in BAT cells
was reduced by RNA silencing, as well as in BAT from Nat8l
knockout mice, the expression of citrate lyase was enhanced.
They proposed that in BAT, as has been suggested for lipid
synthesis in oligodendrocytes in the brain (Moffett et al., 2007),
the NAA to acetyl CoA pathway may be a parallel pathway for
lipogenesis that complements the citrate lyase pathway. How-
ever, unlike in the CNS, the NAA produced in brown adipocytes
would be utilized in the same cell type, rather than being
transferred to a different cell type (e.g., oligodendrocytes) for
metabolism.
The use of NAA for synthesizing a portion of myelin lipids dur-
ing brain development, rather than exclusively using glucose, is
unusual because the brain relies on glucose for its metabolic needs
more than any other organ (Ramos et al., 2011). Adult mammals
utilize glucose as the primary energy deriving metabolite and car-
bon source in the brain, but it is well documented that ketone
bodies are preferred over glucose as an energy source for neurons
and oligodendrocytes during brain development (Edmond et al.,
1987). It has also been shown that acetate is released from the
liver along with ketone bodies to provide another carbon source
to various tissues of the body, including the brain (Ballard, 1972;
Yamashita et al., 2001). Using radiolabeled metabolites Edmond
et al. (1987) showed that ketone bodies were nine times more
effective than glucose for supporting oligodendrocyte respiration
during brain development and myelination. Postnatal myelina-
tion occurs when infant mammals are suckling, and glucose
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FIGURE 2 | Similarities between NAA synthesis and citrate synthesis.
Acetyl CoA derived from pyruvate in neuronal mitochondria can be oxidized
for ATP production in theTCA cycle, or it can be utilized by two different
enzyme pathways to produce metabolites for export to the cytoplasm.
Acetyl CoA and oxaloacetate can be converted to citrate via citrate synthase
(red pathway), or acetyl CoA and aspartate can be converted to NAA via
Asp-NAT (blue pathway). NAA is also synthesized in the endoplasmic
reticulum by cytoplasmic Asp-NAT using acetyl CoA derived from citrate.
Citrate is then metabolized to acetyl CoA within the cell where it was
synthesized, whereas NAA is predominantly transported to other cells such
as oligodendrocytes for metabolism. AAT, aspartate aminotransferase;
AKG, alpha-ketoglutarate; Asp, aspartate; Asp-NAT, aspartate
N -acetyltransferase; CL, citrate lyase; CS, citrate synthase; Glu, glutamate;
Mal, malate; OAA, oxaloacetate; PDC, pyruvate dehydrogenase complex.
availability in the diet is low. Therefore, ketone bodies and acetate
are critical energy metabolites for oligodendrocytes during brain
development, in contrast with adults where glucose is the primary
energy and carbon source.
Traumatic brain injury results in disrupted lipid metabolism,
oxidative damage to, and degradation of mitochondrial phos-
pholipids (Adibhatla et al., 2006; Singh et al., 2006), damage
to subcortical white matter and delayed axonal degeneration
throughout the brain (Hall et al., 2005; Park et al., 2008). Because
NAA-derived acetate is one of the building blocks for myelin
lipid synthesis in the brain, and that NAA levels are substantially
reduced after TBI, we have pursued the concept that a potent
source of acetate which can cross the blood brain barrier would
be useful for the treatment of brain injuries. Glyceryl triacetate
(GTA), the triester of acetate and glycerol, fulﬁlls these criteria.
We have previously shown that orally administered GTA can sub-
stantially increase brain acetate levels (Mathew et al., 2005), and
can be used to increase myelin lipid synthesis in neurological
disorders that involve hypomyelination or demyelination (Arun
et al., 2010b). A logical extension of this ﬁnding is that GTA
may be useful in other brain disorders that involve remyelination,
including TBI.
NAA, ACETATE, AND ENERGY METABOLISM
Traumatic brain injury results in the disruption of brain energy
metabolism and the resultant energy deﬁcit is proportional to
the degree of damage (Marklund et al., 2006). The levels of NAA
and ATP are reduced immediately after brain injury and remain
depressed for hours, days or weeks depending on injury severity
(Signoretti et al., 2001; Tavazzi et al., 2005; Vagnozzi et al., 2005;
Arun et al., 2010a). These reductions are indicative of metabolic
impairment and the depletion of energy stores in the brain, and it
is very likely that the reduction in NAA levels is tied to the loss of
the immediate precursor, acetyl CoA, after brain injury (Vagnozzi
et al., 2007).
NAA AND MITOCHONDRIAL FUNCTION
Patel and Clark (1979) provided the ﬁrst clear experimental evi-
dence that NAA synthesis was associated with mitochondrial
energetics and mitochondrial carbon transport in the brain. Sub-
sequently, a number of investigators have provided multiple
lines of evidence supporting the association between NAA and
neuroenergetics. More recently, Signoretti and associates have
provided extensive preclinical and clinical data in support of this
connection in the context of TBI.However, the precise relationship
between NAA metabolism and energy derivation in the nervous
system remains largely unclear.
We have proposed a multi-functional model of NAA
metabolism involving its synthesis in neuronal mitochondria and
endoplasmic reticulum (Madhavarao et al., 2003; Madhavarao
et al., 2005; Arun et al., 2009). The key aspect of the model is
the connection between NAA metabolism and acetyl CoA gen-
eration and utilization in the nervous system (Ariyannur et al.,
2010a). Because NAA synthesis requires the use of existing acetyl
CoA stores, NAA synthesis can only occur when acetyl CoA lev-
els are in excess of current neuronal metabolic requirements.
This means that when energy reserves are low as in the case
of brain injury, NAA synthesis will be compromised. NAA may
be acting as an acetyl CoA precursor or buffer to help regener-
ate some acetyl CoA during the initial response to brain injury.
This is consistent with data from brain injury studies show-
ing that NAA, ATP, and acetyl CoA are all reduced rapidly after
brain injury and that their levels return in concert with recovery
(Vagnozzi et al., 2007).
We have proposed that another mechanism in which NAA
synthesis serves a neuroenergetic role in mitochondria by facil-
itating the oxidation of glutamate as an additional energy source
(Madhavarao et al., 2003; Madhavarao and Namboodiri, 2006;
Moffett et al., 2007). The synthesis of NAA in mitochondria
requires continuous production of aspartate from oxaloacetate.
This is accomplished by the action of the enzyme aspartate amino-
transferase (also known as glutamate oxaloacetate transaminase
(Figure 3). Aspartate aminotransferase converts oxaloacetate and
glutamate to aspartate and α-ketoglutarate, and the aspartate can
then be converted to NAA, while the α-ketoglutarate can enter
the TCA cycle for energy derivation. This enzymatic reaction
increases α-ketoglutarate formation from glutamate and energy
production via the citric acid cycle. In this way, the demand
for ATP in neurons can be augmented by oxidation of glu-
tamate via the aspartate aminotransferase pathway. Glutamate
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FIGURE 3 | Proposed schematic of NAA synthesis in neuronal
mitochondria. Dashed lines show α-ketoglutarate pathway through GDH
that is bypassed by synthesis through AAT. As more pyruvate enters the
cycle NAA synthesis is increased, aspartate export from mitochondria is
decreased and NAA export is increased. See text for details. AAT, aspartate
amino-transferase (also known as glutamate oxaloacetate transaminase);
Asp-NAT, aspartate N -acetyltransferase; GDH, glutamate dehydrogenase;
NH3, ammonia.
dehydrogenase is another enzyme that converts glutamate to
α-ketoglutarate. Glutamate dehydrogenase is expressed in the
mitochondria and endoplasmic reticulumof neurons and glia, and
it catalyzes the deamination of glutamate to alpha-ketoglutarate
and ammonia using either NAD or NADP as cofactors (Mas-
torodemos et al., 2005, 2009). Once glutamate is imported into
mitochondria it is predominantly destined for conversion to
α-ketoglutarate. By preferentially using the aspartate aminotrans-
ferase reaction instead of the glutamate dehydrogenase reaction to
generate α-ketoglutarate, neuronal mitochondria would circum-
vent the generation of ammonia associated with the glutamate
dehydrogenase reaction. The aspartate aminotransferase reaction
also generates additional aspartate from oxaloacetate, and the
aspartate can then be acetylated by Asp-NAT to form NAA. A
recent study has shown that the decrease in ATP in blast mediated
TBI is associated with a decrease in aspartate aminotransferase
expression in the brain (Arun et al., 2013). Reduced aspartate
aminotransferase activity in neuronal mitochondria would limit
both NAA synthesis from aspartate, and α-ketoglutarate synthe-
sis from glutamate, thus reducing the brain’s capacity to generate
energy.
A number of other ﬁndings in the literature are consistent
with or supportive of these mechanisms. First, inhibition of
aspartate aminotransferase activity by β-methylene-aspartate was
shown to decrease oxygen consumption in the presence of glu-
tamate and malate as energy sources (Cheeseman and Clark,
1988). Second, efﬂux of NAA was increased, whereas that of
aspartate was decreased with increasing concentrations of pyru-
vate in the presence of glutamate and malate as substrates in
mitochondria isolated from rat brain (Patel and Clark, 1979).
Third, ATP synthesis, NAA synthesis, and oxygen consumption
were all reduced similarly in isolated brain mitochondrial prepa-
rations after application of several respiratory chain inhibitors
(Bates et al., 1996). There are numerous experimental paradigms
that have demonstrated decreases in NAA levels when brain
energy metabolism is impaired by different mechanisms. Another
experimental paradigm involved rat and primate models of
progressive striatal neurodegeneration induced by the mitochon-
drial toxin 3-nitropropionic acid (3-NP). In rats treated with
3NP, NAA decrease was observed selectively in the striatum
before any cell loss and was associated with motor dysfunc-
tion. Also, a similar selective and early striatal decrease in NAA
was observed in 3-NP treated primates (Dautry et al., 2000).
The initial decrease in striatal NAA was partially reversed after
3 weeks of 3-NP withdrawal. The mouse model for Hunting-
ton disease is another experimental paradigm wherein decreases
in NAA have been documented. The drop in brain NAA lev-
els commenced at about 6 weeks of age and coincided with the
onset of symptoms (Andreassen et al., 2001). These decreases
in NAA occurred in the absence of any neuronal cell death.
Also, dietary creatine supplementation signiﬁcantly improved
survival, slowed development of brain atrophy and delayed
decreases in NAA (Andreassen et al., 2001). These results also
indicate that the levels of NAA in the brain reﬂect the health of
neurons and their mitochondria, and can therefore act as reli-
able markers for monitoring neuronal energy impairment and
dysfunction.
Using combined proton MRS for NAA levels and 31P MRS
for ATP and ADP levels, Pan and Takahashi (2005) showed that
NAA levels in the uninjured human brain (occipital lobe and
hippocampus) correlate with ADP rather than ATP. These inves-
tigators speculated that this ties NAA synthesis positively to ADP
generation, perhaps indicating that NAA synthesis was responsive
to a decreasing energy charge in brain.
Recent studies with aralar1 knockout mice also provide sup-
port for a bioenergetic role for NAA. Aralar1 knockout mice show
reduced neuronal respiration on glutamate plus malate (Jalil et al.,
2005). It is possible that the acetylation of aspartate by asp-NAT in
neuronal mitochondria could combine with the action of aralar1
to remove product inhibition of the aspartate aminotransferase
reaction, and this would facilitate the conversion of glutamate to
α-ketoglutarate, which can then enter the tricarboxylic acid (TCA)
cycle for energy production (see Figures 2 and 3). Based on the
above model it is reasonable to state that formation of NAA facil-
itates glutamate oxidation, but there is no evidence to indicate
that NAA per se participates directly in any step of mitochondrial
energy production.
As noted above, Nat8l was recently found to be expressed
strongly in BAT, and was associated with increased lipid turnover.
In the same study Nat8l was shown to be present predominantly
in mitochondria in brown fat cells, as opposed to endoplasmic
reticulum (Pessentheiner et al., 2013). Further, it was shown that
Nat8l overexpression increased the number of mitochondria per
cell, and increased oxygen consumption rate.Nat8l overexpression
also dramatically upregulated the expression of BATmarker genes
including UCP1 (uncoupling protein 1). UCP1 acts to uncouple
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oxidative phosphorylation from ATP synthesis by reducing the
proton gradient across the inner mitochondrial membrane, thus
generating heat. Pessentheiner et al. further demonstrated that
overexpression of an Nat8l mutant gene that produces a pro-
tein with no NAA biosynthetic capacity into BAT cells did not
increase BAT marker gene expression indicating that Asp-NAT
enzymatic activity is required for increased BAT gene expression.
These ﬁndings link Asp-NAT not only to mitochondrial func-
tion, but also to gene expression (see Nuclear Protein Acetylation
below).
NAA AND ATP LOSS IN TBI
N-Acetylaspartate levels are substantially reduced after severe
brain injury or stroke, and levels may recover after days or
weeks depending on the severity of the injury (Wardlaw et al.,
1998; Signoretti et al., 2010, 2011; Vagnozzi et al., 2010). Recov-
ery of NAA to normal levels is typically seen after milder brain
injuries, but not in the case of severe injuries, or in the case of
multiple milder injuries spaced closely in time as often occurs
in contact sports. Studies employing experimental TBI in rats
strongly link NAA to neuronal energetics. Signoretti et al. (2001)
used a sensitive HPLCmethod to show that moderate experimen-
tal TBI led to maximal reductions in NAA at 15 h post-injury
(−46%) and maximal ATP reductions at 6 h post-injury (−57%).
The levels of both metabolites recovered to near normal levels
by 5 days after injury indicating that moderate TBI results in a
severe energy impairment that does not involve extensive neu-
ronal death. In the same study severe TBI was found to result in
even greater energy depletion with NAA and ATP levels falling
by ∼60% by day ﬁve after injury, with no indication of recov-
ery of normal levels for either compound suggesting extensive
and permanent loss of neurons. Levels of ATP and NAA were
depleted even further when severe TBI was coupled with tempo-
rary hypoxia-hypotension (90 and 80%, respectively 48 h after
injury).
Subsequent studies deﬁned awindowof increased vulnerability
to a second injury event whereby a single moderate TBI resolved
after ∼5 days, with recovery of NAA and ATP levels (Vagnozzi
et al., 2007; Signoretti et al., 2011). However, when a second mod-
erate TBI event occurred 3 days after the initial injury, then NAA
and ATP levels did not recover, and outcomes were substantially
poorer. It was also found that if the second moderate injury event
occurred ﬁve or more days after the ﬁrst event, when NAA and
ATP levels had already recovered, then the second event also was
followed by recovery of brain energy stores. These ﬁndings indi-
cate that the energy depletion associated with moderate brain
injury leaves the brain much more vulnerable to a second injury
event.
NON-GLUCOSE ENERGY SOURCES IN THE TREATMENT OF TBI
The brain derives most of its energy from glucose, but the brain
can also make use of alternate energy sources including ketone
bodies, glutamate/glutamine, lactate, and acetate. Studies on the
response of neurons to hypoglycemia show that neurons canmake
use of a number of alternative substrates for energy derivation
when glucose levels are insufﬁcient (Amaral, 2013). TBI results
in an energy deﬁcit in cerebral tissue (Vespa et al., 2005) with a
concomitant increase in the uptake and utilization of ketone bod-
ies (White and Venkatesh, 2011). Attempts to compensate for the
energy deﬁcit by providing nutrition in the form of glucose or
other carbohydrates to TBI and stroke patients can result in hyper-
glycemia and exacerbate secondary damage (Ginsberg et al., 1980;
Welsh et al., 1980). This has led some researchers to explore the
use of non-carbohydrate sources of nutrition to improve recov-
ery from stroke and TBI. Robertson et al. (1992) used several
non-carbohydrate energy sources, as well as 24 h fasting, in an
experimental model of ischemia in rats and compared infarct vol-
ume between groups. They administered 1,3-butanediol, triacetin
(GTA), tributyrin, and long- and medium-chain triglycerides, as
well as a combination of triacetin and tributyrin to rats subjected
to temporary middle cerebral artery occlusion. The fasted group
had the smallest infarct volumes, and the 1,3 butanediol group
had the next smallest infarct volumes. The triacetin/tributyrin
group also showed reduced infarct volumes relative to the con-
trol group that was given a diet of normal rat chow. These
ﬁndings indicate that diets which mimic fasting (ketogenic) con-
ditions provide amore suitable post-injury nutritional support for
CNS repair.
Lactate has been studied as an alternative nutritive energy
source after experimental TBI in rats (Rice et al., 2002). Using
the ﬂuid percussion model of TBI Rice and coworkers found that
100 mM lactate infusion 30 min after injury resulted in signif-
icantly increased ATP levels in the ipsilateral hemisphere at 3 h
post injury. Morris water maze performance on days 11 through
15 after injury were also signiﬁcantly improved with 100 mM
lactate treatment. A more recent study found no improvement
in brain energy status with post-injury lactate infusion in rats
subjected to severe TBI and the authors attributed this to the
reductions in NAD+ which then prevented signiﬁcant pyruvate
synthesis from lactate (Prieto et al., 2011). Prins et al. (2004)
used 3 h of β-hydroxybutyrate infusion beginning immediately
after injury and found that the injury resulted in an 8.5-fold
increase in uptake of the ketone body into brain, and that CO2
derived from radiolabeled β-hydroxybutyrate increased by nearly
11%. Treatment also reversed the 20% drop in ipsilateral ATP
levels observed after injury in the saline treated group. Prins
(2008) summarizes the ﬁndings by stating: “Whether ketosis is
achieved by starvation or administration of a ketogenic diet,
the common underlying conditions of low plasma glucose in
the presence of an alternative substrate (ketones) have consis-
tently shown neuroprotective effects after various types of brain
injuries.”
Acetylcarnitine has been shown to reduce neurological deﬁcits
after global cerebral ischemia and reperfusion (Rosenthal et al.,
1992) and has also been found to reduce lesion size and improve
neurological outcomes in young rats subjected to controlled corti-
cal impact injury (Scaﬁdi et al., 2010a). Scaﬁdi et al. concluded
that acetylcarnitine improved cerebral energy metabolism and
therefore reducing necrotic cell death due to metabolic failure.
This conclusion is supported by studies of experimental spinal
cord injury in rats where treatment with acetylcarnitine signif-
icantly improved acute mitochondrial function and long term
motor function recovery (Patel et al., 2012). Scaﬁdi et al. (2010b)
used 13C-MRS to show that when acetylcarnitine that was mass
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labeled on the acetyl moiety was injected into 21- to 22-day-
old rats the acetate group was utilized for energy derivation in
the TCA cycle, and also became incorporated into a number of
brain metabolites. The labeled metabolites that were detected
in the mass spectra 2 h after administration included gluta-
mate, glutamine, taurine, creatine, lactate, NAA, and GABA.
This labeling pattern indicates metabolism of the acetyl group
of acetylcarnitine through the TCA cycle in both neurons and glial
cells.
Our laboratory has been investigating the use of GTA as a
method of delivering high doses of acetate to the brain. GTA
is a hydrophobic molecule that crosses the blood brain barrier
and enters cells in the brain without the need of transporters.
This high degree of bioavailability may be an important factor
in the treatment of brain injury due to compromised cerebral
circulation, which can limit the distribution of water soluble com-
pounds. In neuronal and glial cytoplasm GTA is rapidly broken
down by non-speciﬁc esterases and lipases to generate free acetate
and glycerol. Using the unilateral controlled cortical impactmodel
of TBI in rats we found that GTA administration signiﬁcantly
improved NAA and ATP levels in the injured hemisphere 4 and
6 days after injury (Arun et al., 2010a). Therefore, the reduction
in brain energy stores resulting from brain injury can be partly
reversed by the administration of GTA as a non-glucose energy
source. Improvements in motor performance on a Rotarod bal-
ance test were also signiﬁcant 3 days after injury, suggesting that
GTA administration may accelerate post-injury recovery rates.
The partial restoration of NAA we observed in the injured hemi-
sphere after GTA treatment contrasts with the earlier ﬁnding that
high doses of GTA given over time to uninjured mice did not
increase the normal levels of NAA in the brain (Mathew et al.,
2005). The beneﬁcial effects of GTA are likely to be a due to
the signiﬁcant drop in brain acetyl coenzyme A levels associated
with TBI (Vagnozzi et al., 2007), which would affect both ATP and
NAA synthesis rates. Increasing acetate availability after TBI could
partly compensate for the reduced availability of acetyl CoA and
increase bothATP andNAA synthesis. GTA has also been found to
reduce neuroinﬂammation (Reisenauer et al., 2011; Brissette et al.,
2012; Soliman et al., 2012), which may increase its effectiveness
after TBI.
Acetate is not technically a ketone body because it is metabo-
lized by different enzymes than acetoacetate or β-hydroxybutyrate.
However, like ketone bodies it can be used for energy derivation
and for the synthesis of fatty acids. Therefore, by providing free
acetate, GTA may be working in a fashion analogous to ketone
bodies, but without the same restriction to young animals and the
developingbrain. Acetate canbe converted to acetyl coenzymeAby
the action of acetyl coenzyme A synthetase (Nikolau et al., 2000).
Two forms of acetyl coenzyme A synthetase exist in cells, a mito-
chondrial form (AceCS2) involved in energy metabolism (Fujino
et al., 2001), and a nuclear-cytosolic form (AceCS1) involved in
lipid synthesis and protein acetylation reactions (Luong et al.,
2000; Wellen et al., 2009; Ariyannur et al., 2010b). Therefore, the
acetyl CoA produced from GTA can go on to be oxidized in the
TCA cycle for energy production in mitochondria (AceCS2), or
can enter lipid synthetic pathways for the productionofmembrane
and myelin lipids in the cytoplasm (AceCS1).
AceCS1 AND AceCS2 LOCALIZATION IN THE BRAIN
A primary factor required for NAA-derived acetate to be used for
energy derivation, lipid synthesis, or protein acetylation reactions
is the expression of the acetyl CoA synthetase enzymes AceCS1
and AceCS2 (Figure 4). AceCS1 had long been thought to be a
cytoplasmic enzyme that was primarily involved in acetyl CoA
production for fatty acid synthesis (Woodnutt and Parker, 1978;
Imesch and Rous, 1984). However, more recent studies have indi-
cated that AceCS1 is a nuclear-cytoplasmic enzyme that is also
involved in protein acetylation reactions including histone acety-
lation (Takahashi et al., 2006; Wellen et al., 2009). Supporting this
observation,wehaveused antibodies toAceCS1 and showed that in
the adult rat brain the predominant localization is nuclear, rather
than cytoplasmic, and that expression of AceCS1 was substan-
tially upregulated after experimental TBI in rats (Ariyannur et al.,
2010b). The greatest increase in AceCS1 expression after TBI was
in the nuclei of cells throughout the brain, including both neural
and glial cells, but some increased cytoplasmic staining was also
observed (Figure 5). Previously it has been shown that mRNA lev-
els for the NAA-degrading enzyme ASPA are upregulated as much
as fourfold after experimental TBI in rats (Vagnozzi et al., 2007).
These ﬁndings suggest that the capacity to generate and utilize
NAA-derived acetate for lipid synthesis and protein acetylation
reactions is substantially increased in response to brain injury (see
Nuclear Protein Acetylation and Cytoplasmic Protein Acetylation
below).
AceCS2 is a mitochondrial enzyme that converts free acetate
into acetyl CoA for energy derivation through the TCA cycle,
and is expressed most strongly in cardiac and skeletal muscle
and BAT (Fujino et al., 2001; Sakakibara et al., 2009). AceCS2
is also expressed at relatively lower levels in the brain. We
used two different antibodies to localize AceCS2 in the brain
and using dual labeling found it to be associated primarily
with GFAP-positive astrocytes (Figure 6A). In agreement with
studies on the tissue distribution of AceCS2 (Fujino et al., 2001)
FIGURE 4 |AceCS1 andAceCS2 have different subcellular distributions.
AceCS1 is localized in the cell cytoplasm where it generates acetyl CoA for
lipid synthesis and cytoplasmic protein acetylation reactions. AceCS1 is
also localized in cell nuclei where it generates acetyl CoA for histone and
other protein acetylation reactions. AceCS2 is localized in mitochondria
where it supplies acetyl CoA for energy derivation via theTCA cycle.
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FIGURE 5 | AceCS1 expression is increased afterTBI. AceCS1
immunoreactivity in control (A,C) and 3 days after controlled cortical impact
injury on the side ipsilateral to the injury (B,D–F). Lower magniﬁcation images
of layer V of neocortex are shown in (A,B) indicating the increased expression
of AceCS1 after injury, with higher magniﬁcation of layer V shown in (C,D).
Arrows in (C,D) show the substantial increase in AceCS1 expression in the
nuclei of larger cortical pyramidal cells. (E) (layer V neocortex) and (F) (CA3
region of hippocampus) show double staining for AceCS1 (orange) and GFAP
in astrocytes (purple). A large increase in expression was observed for both
AceCS1 and GFAP 3 days after injury. Arrows in (E,F) show astrocytes with
AceCS1 positive nuclei. Bar = 30 μm (A,B,E,F), 10 μm (C,D). Methods given
in Ariyannur et al. (2010b).
AceCS2 expression was relatively low in the brain. Strong AceCS2
immunoreactivity was observed in punctuate structures that
could represent mitochondria in astrocyte end feet on blood
vessels and on the surface of other cells including oligoden-
drocytes (Figure 6B). AceCS2 was also associated with similar
punctuate structures in the pia matter. It is possible that these
apparent intercellular contacts between astrocytes and endothe-
lial cells and oligodendrocytes indicate that astrocytes are making
use of acetate from the blood stream, as well as NAA-derived
acetate from oligodendrocytes as an energy source (see Figure 7
below).
NAA AND METABOLIC INTERACTIONS BETWEEN NEURONS AND GLIA
The classical view of brain energetics focused on glucose as the pri-
mary and almost exclusive energy source for the brain. However,
the emerging view of energy utilization in the brain is that other
metabolites are used by the brain as signiﬁcant energy sources
including glutamate and acetate, which are utilized extensively
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FIGURE 6 | AceCS2 immunoreactivity in the rat brain using an antibody
generated against a 14 AA sequence from the C-terminus of murine
AceCS2 (1:5000 dilution). Immunoreactivity in the adult rat brain was only
observed in small punctuate structures, especially in white matter tracts, on
some blood vessels and in the pia matter. (A) Confocal z -series images of
immunoﬂuorescence for AceCS2 (green) and the astrocyte marker GFAP (red)
at the cortical surface including the pia matter (blue indicates DAPI staining of
cell nuclei). Colocalization of AceCS2 and GFAP appears as yellow. This series
of images show the merged images at various depths within the tissue slice.
AceCS2 was associated with punctuate structures in astrocytes. (B) High
magniﬁcation image of immunohistochemistry in adult rat corpus callosum.
The punctuate structures were often closely apposed to blood vessels
(arrows) or oligodendrocyte cell bodies (arrowheads). The stained structures
ranged in size from ∼½ to 1 micron. Bars in (A,B) = 10 μm.
by astrocytes during normal brain function and in response to
pathology. Under resting conditions the metabolic rate of acetate
utilization corresponds to between 15 and 25% of the glucose uti-
lization rate (Dienel and Cruz, 2006). When acetate is utilized as
a substrate for cerebral metabolism less citrate is used (reduced
citrate lyase activity) thus sparing citrate for other uses (Rae et al.,
2012). Astrocytes provide the major interface between circulating
nutrients and the other cell types in the brain including neurons
and oligodendrocytes. As a primary part of the blood brain barrier
astrocytes act as a selectiveﬁlter andnutrient distribution system to
the other cell types that donot have suchdirect access to circulating
nutrients. Astrocytes are also the principle users of acetate reaching
the brain via the circulation due to their robust uptake capacity,
and they oxidize much of the acetate for energy derivation via the
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FIGURE 7 | Schematic diagram depicting some of the metabolic
trafficking between neurons, oligodendrocytes, and astrocytes. A major
intercellular cycle between neurons and astrocytes is exempliﬁed by the
glutamate-glutamine cycle. A percentage of glutamate is not recycled
however, and instead is oxidized for energy derivation in theTCA cycle of
neurons and astrocytes. A major metabolite cycle also exists between
neurons and oligodendrocytes via NAA that is transferred from axons to
oligodendrocytes at axo-glial contact zones between the innermost
oligodendrocyte plasma membrane in a myelin segment and the axonal
membrane. ASPA in the oligodendrocytes generates free acetate which can
then be converted to acetyl CoA by AceCS1, which can then go on to be
utilized for fatty acid synthesis, cytoplasmic protein acetylation reactions, and
nuclear histone acetylation (blue lines). It is possible that some acetate
derived from NAA in oligodendrocytes is transferred to astrocytes for energy
derivation though the enzyme AceCS2 present in mitochondria in astrocyte
end feet and cellular contact zones. AceCS2 in astrocytes is also in a position
to capture blood borne acetate for energy derivation. See Figures 2 and 3 for
details of the reactions in neuronal mitochondria. It is also possible that some
NAA-derived aspartate in oligodendrocytes is recycled back to neurons. AAT,
aspartate aminotransferase; AceCS1, acetyl CoA synthase-1; AceCS2, acetyl
CoA synthase-2; AKG, α-ketoglutarate; ASP, aspartate; ASPA, aspartoacylase;
aspNAT, aspartate N -acetyltransferase; CL, ATP citrate lyase; GLN, glutamine;
GLU, glutamate; GS, glutamine synthase; NH3, ammonia; PAG, phosphate
activated glutaminase.
TCA cycle (Waniewski and Martin, 1998). However, NAA-derived
acetate as well as acetate from other intracellular sources (acetyl
CoA, acetylcarnitine, acetylated proteins, etc.) may be utilized
locally in the cells where it is generated if an acetyl CoA syn-
thase enzyme is present. For example, some larger neurons in the
brainstem and spinal cord of rats express bothASPA (Moffett et al.,
2011) and AceCS1 (Ariyannur et al., 2010b) and therefore may be
capable of not only NAA synthesis, but also NAA catabolism and
regeneration of acetyl CoA from the liberated acetate.
The exceptionally high level of NAA in the nervous system,
coupled with the fact that NAA diverts some acetyl CoA from
other potential uses, suggests that NAA serves as an acetyl group
(carbon) storage molecule that is synthesized when glucose is
in excess of minimal system needs. The stored acetate can be
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reclaimed by the action of ASPA, followed by the action of
AceCS1 or AceCS2 to regenerate acetyl CoA. Because some pro-
portion of NAA is transferred to oligodendrocytes for metabolism
(Chakraborty et al., 2001) it is part of the metabolic trafﬁck-
ing system between cell types in the nervous system. Studies
on the comparative utilization of acetate and glucose revealed
a close coupling of the TCA cycle in astrocytes and neurons,
and suggest highly cooperative energy derivation in the two cell
types (Serres et al., 2008). This coupling may be increased after
brain injury. Bartnik-Olson et al. (2010) used the ﬂuid percus-
sion model of TBI to show that oxidation of glucose is reduced
in neurons after injury, but that acetate utilization in astrocytes
is increased indicating that astrocytes make use of an alternate
energy source to maintain brain energy levels in response to
injury. Astrocytes increased their incorporation of acetate into
glutamine in a time dependent manner during the hypometabolic
period after injury, and the trafﬁcking of metabolites between
astrocytes and neurons was maintained during the recovery
period.
Astrocytes have received the most attention with regard to
metabolic trafﬁcking between cell types in the brain, but recently
some authors have stressed the importance of oligodendrocytes in
intercellular metabolic interactions. This has led to the concept of
neuron-oligodendrocyte-astrocyte interactions wherein metabo-
lites given off by one cell type are taken up and utilized by other
cell types (Amaral et al., 2013). NAA is one of the key metabolites
transferred from neurons to oligodendrocytes to support vari-
ous metabolic demands for acetyl CoA (Figure 7). The aspartate
derived from NAA can be utilized for protein synthesis or con-
verted to oxaloacetate by transamination for further metabolism.
It is also possible that some of the aspartate is recycled back to
neurons.
NAA AND PROTEIN ACETYLATION – NAA AS AN ACETYL
GROUP RESERVOIR
Early indications that NAA was involved in acetylation reac-
tions were provided by Buniatian et al. (1965) who reported that
acetylcholine and acetylglucosamine could be synthesized from
NAA-derived acetate. They also found that when rat brain cortical
slices were incubated in the presence of added glucose, NAA was
released to the medium. When glucose was omitted, NAA levels
were reduced and aspartate levels in the media increased. This
is consistent with the fact that acetyl CoA is required for NAA
synthesis. Pyruvate is the end product of glycolysis, so as glucose
levels increase so do the levels of pyruvate, which is the immediate
precursor for acetyl CoA synthesis in mitochondria (see Figures 2
and 3).
NUCLEAR PROTEIN ACETYLATION
AceCS1 functions to utilize free acetate, and convert it into metab-
olizable acetyl CoA. Free acetate originates from several sources
including the activity of gut bacteria, and the enzyme acetyl CoA
hydrolase, which breaks down existing acetyl CoA to release the
acetate. This happens in the liver under ketogenic conditions
and the liberated acetate is released to the circulation along with
ketone bodies (Grigat et al., 1979; Woodnutt and Parker, 1986).
The acetate can be taken up from the circulation by other tis-
sues and reconverted to acetyl CoA via AceCS1. AceCS1 was
originally thought to be a lipogenic enzyme involved in the uti-
lization of acetate primarily for lipid synthesis (Ikeda et al., 2001).
However, another recently discovered function of AceCS1, the
nuclear-cytosolic form of the enzyme (Ariyannur et al., 2010b),
is to provide acetyl CoA for nuclear histone acetyltransferase
enzymes involved in epigenetic gene regulation (Takahashi et al.,
2006). In order for transcription-associated enzymes such as RNA
polymerase to have access to the appropriate DNA strands and
for gene transcription to proceed histone acetylation is required
to dissociate histones from DNA, and this is accomplished by the
action of histone acetyltransferases (HATs) that act to acetylate
lysine residues on histone proteins. Histone deacetylase enzymes
(HDACs) act to deacetylate histones and facilitate their bind-
ing to DNA thus silencing gene transcription. Inhibiting HDACs
prolongs the dissociation of histone proteins from DNA, per-
mitting enhanced gene transcription. Dash et al. (2009) have
shown that the HDAC inhibitor sodium butyrate improves learn-
ing and memory in rats following experimental TBI. Inhibiting
histone deacetylation may enhance gene transcription for cellu-
lar repair mechanisms and neuronal plasticity. The drop in acetyl
CoA levels after TBI could limit the ability of cells to maintain
proper transcription levels due to reduced histone acetylation.
We have found that AceCS1 is strongly upregulated in neuronal
and glial cell nuclei after TBI (Ariyannur et al., 2010b), suggest-
ing increased enzymatic capacity to synthesize acetyl CoA from
free acetate in response to brain injury. We further hypothe-
sized that the strong expression of AceCS1 in cell nuclei provides
a mechanism to recycle free acetate generated by the action of
HDACs. Reclaiming this acetate would help maintain nuclear
acetyl CoA levels especially during times of increased gene tran-
scription, such as in response to injury. ASPA (Hershﬁeld et al.,
2006;Moffett et al., 2011) andAceCS1 (Ariyannur et al., 2010b) are
localized extensively in the nuclei of oligodendrocytes, and there-
fore are in a position to provide additional acetyl CoA for nuclear
HAT reactions. It is reasonable to hypothesize that this arrange-
ment provides a means for targeting metabolism of NAA-derived
acetate to the cell nucleus of oligodendrocytes for intra-nuclear
synthesis of acetyl CoA to support acetyltransferase reactions.
Such an arrangement would be more robust than relying solely
on diffusion of cytoplasmic acetyl CoA into the nucleus, espe-
cially at times of increased transcription associated with brain
injury.
CYTOPLASMIC PROTEIN ACETYLATION
One additional deﬁcit associated with reduced acetyl CoA avail-
ability after TBI involves the posttranslational acetylation of
proteins outside of the nucleus in the endoplasmic reticulum
and organelles such as mitochondria. Many cell types that have
active protein secretory pathways through the endoplasmic retic-
ulum, such as neurons and oligodendrocytes, are sensitive to
disorders of protein mis-folding. Evidence indicates that acety-
lation and deacetylation of nascent polypeptide chains in the
endoplasmic reticulum is required for stabilization and correct
folding (Costantini et al., 2007; Spange et al., 2009). Acetyl CoA is
required for the acetyltransferase reactions involved in acetylation
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at lysine sites on newly synthesized proteins and these acetyla-
tion reactions can hinder ubiquitination and therefore prevent
protein degradation (Sadoul et al., 2008). As such, the substantial
reductions in brain acetyl CoA levels that occur after brain injury
could have a negative impact on protein folding and stabilization.
Misfolded proteins are targeted for destruction via endoplasmic
reticulum associated degradation (ERAD). An example of this
can be seen in knockout mice for the NAA-degrading enzyme
ASPA. In ASPA-deﬁcient mice, which cannot hydrolyze NAA into
acetate and aspartate, there is a severe loss of several impor-
tant myelin associated proteins including myelin basic protein
and PLP/DM20 proteolipid proteins, combined with perinuclear
retention of these proteins. These are indicators of impairment
in protein trafﬁcking in oligodendrocytes (Kumar et al., 2009).
Oligodendrocytes are very susceptible to endoplasmic reticulum
stress (ERS) associated with disruptions in protein synthesis and
trafﬁcking (Lin andPopko,2009). Protein acetylation anddeacety-
lation are also key regulatory mechanisms for controlling enzyme
function in both the cytoplasm and in mitochondria (Guan and
Xiong, 2010). It is quite possible that NAA-derived acetate is uti-
lized to provide additional acetyl CoA for protein stabilization
and enzyme regulation in oligodendrocytes after TBI-induced loss
of acetyl CoA, but this possibility has not been investigated to
date.
POTENTIAL ROLE OF NAA IN DOPAMINERGIC
NEUROTRANSMISSION
Recently, two laboratories have generated mice in which the gene
for Asp-NAT (Nat8l) is knocked out (Furukawa-Hibi et al., 2012;
Ariyannur et al., 2013).MRSanalysis of theNat8l± (heterozygous)
mice indicated signiﬁcant reductions (∼30%) in forebrain NAA
levels and the mice showed reduced vertical activity in open ﬁeld
tests (Ariyannur et al., 2013). Heterozygous Nat8l± mice also dis-
played increased responsiveness to methamphetamine. In studies
of homozygous Nat8l−/− mice it was found that they exhib-
ited reduced social interactions when in unfamiliar surroundings,
as well as increased grooming and rearing in open ﬁeld tests
(Furukawa-Hibi et al., 2012; Ariyannur et al., 2013). Additionally,
the mice had reduced levels of brain derived neurotrophic factor
mRNA in the prefrontal cortex and hippocampus and decreased
glial cell derived neurotrophic factor mRNA in the striatum
and hippocampus. Earlier gene knockdown studies with anti-
senseNat8l oligonucleotides demonstrated that reducedAsp-NAT
expression in the nucleus accumbens enhanced responsiveness to
methamphetamine via increased dopamine release and reduced
dopamine uptake (Niwa et al., 2007; Niwa and Nabeshima, 2011).
These studies implicated Asp-NAT in driving tumor necrosis fac-
tor alpha expression which in turn reduced expression of brain
derived and glial cell derived neurotrophic factors. The emerging
view of NAA as either directly or indirectly involved in reg-
ulation of dopaminergic neurotransmission may open up new
avenues of research and potential opportunities for therapeutic
interventions into a variety of neurological and psychiatric dis-
orders, including TBI which involves substantially reduced NAA
levels.
Recent advancements including the cloning of the Asp-NAT
gene now make it possible to selectively reduce NAA levels in key
brain areas and to reverse the decreases by NAA supplementa-
tion with the hydrophobic methyl-ester of NAA to determine if
the NAA reductions are associated with the pathologies observed
in a wide variety of brain disorders and pathologies, including
TBI. The RNAi knockdown method allows for selective reduc-
tion of NAA in speciﬁc brain regions of interest, which will
mimic the reductions seen in various CNS disorders. Demon-
stration that NAA has critical roles in modulating dopaminergic
neurotransmission would transform this ﬁeld of research and
possibly open up new therapeutic targets for a number of CNS
disorders.
NAA AND NAAG SYNTHESIS
N-Acetylaspartate is required for the synthesis of the dipep-
tide NAAG. NAAG is synthesized in neurons by the action of
two recently discovered enzymes, designated NAAG synthetases
(Becker et al., 2010; Collard et al., 2010). These two enzymes are
encodedby genes for theATPGRASP family proteinsRIMKLAand
RIMKLB. These enzymes are glutamate ligases that act to couple
glutamate to an acceptor molecule. NAA is the primary acceptor
for RIMKLA,whereas citrate is an additional acceptor for RIMKLB
that also forms beta-citylglutamate. NAAG has been described as
the most prevalent neuroactive peptide in the mammalian CNS
(Neale et al., 2000). NAAG has been implicated in neurotransmit-
ter release modulation (Adedoyin et al., 2010; Walder et al., 2012;
Zuo et al., 2012; Romei et al., 2013) possibly via action at type 3
metabotropic glutamate receptors (Zhao et al., 2001; Neale, 2011).
A number of studies have demonstrated that the concentration
of NAA directly affects NAAG synthesis wherein higher concen-
trations NAA lead to increased NAAG synthesis (Gehl et al., 2004;
Arun et al., 2006; Collard et al., 2010) and lower concentrations of
NAA result in reduced NAAG synthesis (Ariyannur et al., 2013).
Because NAA is a direct precursor for NAAG synthesis it is likely
that reduced NAAG levels that are observed in experimental TBI
(Vagnozzi et al., 2007) are due to reductions in the concentration
of immediate precursor, NAA. Reduced NAAG levels after brain
injury could have deleterious effects on neurotransmitter release
modulation or other brain functions.
NAAG CATABOLISM AND BRAIN INJURY
N-acetylaspartylglutamate is catabolized primarily by the enzyme
glutamate carboxypeptidase II (GCPII, and also known as NAAL-
ADase) which hydrolyzes NAAG into NAA and glutamate (Blakely
et al., 1988). GCPII is expressed on astrocytes (Berger et al.,
1999) and has a high degree of similarity with prostate speciﬁc
membrane antigen (Berger et al., 1999; Tiffany et al., 1999). Lim-
iting NAAG hydrolysis with GCPII inhibitors has been found
to be protective in brain injury models, and this is thought to
occur by preventing glutamate release from NAAG, thus reduc-
ing post-injury excitotoxicity (Slusher et al., 1999; Vornov et al.,
1999; Thomas et al., 2000). However, NAAG injected into the rat
brain immediately beforemiddle cerebral artery occlusion reduced
infarct volume, and this effect was attenuated by co-treatmentwith
a non-selective metabotropic glutamate receptor antagonist sug-
gesting that NAAG is neuroprotective via binding tometabotropic
glutamate receptors (Lu et al., 2000). Reducing NAAG hydroly-
sis with GCPII inhibitors in a rat model of TBI with secondary
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hypoxia was found to signiﬁcantly reduce cell death in the hip-
pocampus by maintaining NAAG levels and reducing glutamate
release from NAAG (Gurkoff et al., 2013). Overall, the results
point to intact NAAG as having neuroprotective effects through
metabotropic glutamate receptors, and NAAG hydrolysis having
excitotoxic effects through the action of the released glutamate on
ionotropic glutamate receptors.
FINAL THOUGHTS
N-Acetylaspartate is by far the most concentrated acetylated
metabolite in the human brain, and its concentration is exquisitely
responsive to brain injury. One possible explanation for the rapid
and substantial drop in NAA levels immediately after injury
is that NAA is providing local acetate as one of the mecha-
nisms of response to depleted acetyl CoA that occurs due to
injury-related energy depletion and metabolic depression. NAA
synthesis requires the consumption of acetyl CoA, and the hydrol-
ysis of NAA via ASPA generates local free acetate which can only
be reconverted to acetyl CoA if either AceCS1 or AceCS2 are
expressed at or near the site of NAA hydrolysis. Oligodendro-
cytes are one cell type in the brain that strongly express both
ASPA and AceCS1 in their cytoplasm and nuclei, and therefore
it seems likely that oligodendrocytes are a major site of acetyl
CoA regeneration from NAA-derived acetate. The most parsi-
monious explanation for this arrangement is that NAA is acting
as component of a neuron-oligodendrocyte metabolite trafﬁck-
ing system supporting oligodendrocyte metabolism during brain
development, in the adult brain, and in response to brain injury.
In addition, the strong expression of ASPA and AceCS1 in oligo-
dendrocyte nuclei suggests that NAA-derived acetate is, in part,
utilized to supply acetyl CoA for histone acetyltransferase enzymes
required for increased gene transcription associated with injury-
response mechanisms. NAA-derived acetate can also be used
for myelin synthesis to repair myelin sheaths damaged during
brain injury. In return, oligodendrocytes can supply neuronal
axons with needed metabolites required for maintenance and
repair.
Many gaps remain in our knowledge of the functional roles
of NAA in the nervous system, and in other tissues such as BAT.
Top among these is the ﬁnal fate and distribution of NAA-derived
acetate in the brain during development, and under different phys-
iological and pathological conditions. It remains to be determined
what proportion of NAA-derived acetate is directed to protein
acetylation, lipid synthesis or energy derivation in the normal
and injured brain. Other possible roles for NAA such as activa-
tion of second messenger systems, allosteric regulation of enzyme
activity, or gene activation remain under-investigated and mostly
unknown. Accumulating evidence links NAA to the regulation
of dopamine release, but this requires further study to establish
the connection and determine the underlying mechanisms. Evi-
dence for a mitochondrial localization of Asp-NAT is mounting,
but the mechanisms whereby Asp-NAT is targeted to mitochon-
drial membranes or matrix remain elusive due to a lack of an
N-terminal mitochondrial targeting sequence. Additionally, it is
unknown how much of a drop in NAA concentration in vivo is
necessary to have an impact on NAAG synthesis, and therefore
affect NAAG related functions. A less discussed aspect of NAA
metabolism involves the fate of NAA-derived aspartate afterASPA-
mediated hydrolysis. Is the resultant aspartate utilized primarily
for protein synthesis or does it enter the TCA cycle as oxaloacetate
for energy derivation? It is also possible some of the aspartate is
recycled back to neurons for use there. Another area requiring
further attention is the question of the identity of NAA trans-
porters involved inmovingNAAout of mitochondria, andmoving
NAA from neuronal axons to oligodendrocytes. Unraveling these
uncertainties will be critical for understanding the complex
nature of the roles played by NAA in the healthy and injured
brain.
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